Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 03, 2015 12:21 PM ET

Pharmaceuticals

Company Overview of Jounce Therapeutics, Inc.

Company Overview

Jounce Therapeutics, Inc. engages in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Its immunotherapies are designed to harness the patient's immune system to seek out and attack cancerous cells and tumors. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

1030 Massachusetts Avenue

Cambridge, MA 02138

United States

Founded in 2012

Phone:

617-585-2000

Fax:

617-859-2891

Key Executives for Jounce Therapeutics, Inc.

Chief Executive Officer
Age: 56
Co-Founder
Co-Founder
Compensation as of Fiscal Year 2015.

Jounce Therapeutics, Inc. Key Developments

Jounce Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 12:40 PM

Jounce Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-12-2015 12:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Richard Murray, Chief Executive Officer.

Jounce Therapeutics, Inc. Presents at 2015 Jefferies Immuno-Oncology Summit, Apr-15-2015 12:00 PM

Jounce Therapeutics, Inc. Presents at 2015 Jefferies Immuno-Oncology Summit, Apr-15-2015 12:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Richard Murray, Chief Executive Officer.

Jounce Therapeutics, Inc. Appoints Deborah Law, D. Phil., to the Position of Chief Scientific Officer

Jounce Therapeutics, Inc. announced the appointment of Deborah Law, D. Phil., to the position of chief scientific officer. Dr. Law brings to Jounce nearly two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology. Dr. Law joins Jounce from Merck, where she most recently served as vice president of Therapy Area Biology for Immunology, Oncology and Immunomodulators. In this role, she was responsible for bringing cancer immunotherapy compounds from discovery to the clinic. Prior to Merck, Dr. Law served as the chief scientific officer for Ablynx n.v. and held various research positions in biotechnology companies including PDL Biopharma, EOS Biotechnology and Cor Therapeutics.

Similar Private Companies By Industry

Company Name Region
IVAX Laboratories, Inc. United States
Bayer HealthCare Pharmaceuticals Inc. United States
Esperance Pharmaceuticals, Inc. United States
Phytomedics, Inc. United States
Clintriad Pharma Services United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 17, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Jounce Therapeutics, Inc., please visit www.jouncetx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.